ArticleEClinicalMedicine2025

Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655].

Thierry Passeron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.